To report the visual outcome of polypoidal choroidal vasculopathy receiving combined treatment with photodynamic therapy using Visudyne and intravitreal ranibizumab injections, and to analyze the ...

Polypoidal choroidal vasculopathy (PCV) is an interesting, multi-faceted disease. First described by Yannuzzi in 1980, it came to be known by various terms such as posterior uveal bleeding ...

Intravitreal ranibizumab significantly improved visual acuity in eyes with polypoidal choroidal vasculopathy but not in eyes with typical neovascular age-related macular degeneration, a study ...

SAN FRANCISCO – Brolucizumab demonstrated superior anatomic results and maintained best corrected visual acuity (BCVA) in patients with polypoidal choroidal vasculopathy (PCV) at week 96 of the ...

Pulsatile polypoidal vessel in polypoidal choroidal vasculopathy is an important characteristic that has not been reported with any other chorioretinal diseases and could assist in understanding ...

HealthDay News — Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal ...

(HealthDay)—Combination therapy consisting of ranibizumab plus verteporfin photodynamic therapy (vPDT) is superior to ranibizumab monotherapy for treatment of eyes with polypoidal choroidal ...

6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy. Wednesday, December 9, 2009 Research News. Advertisement ...

In addition, “in EVEREST II, the rates of complete polypoidal lesion regression at months 3, 6, 12, and 24 were consistently higher for combination therapy than for monotherapy at months 3 ...

The presentation, titled “Efficacy and Safety of OPT-302 in combination with Ranibizumab for Polypoidal Choroidal Vasculopathy,” was held on Sunday, May 1, 2022, and appeared in a session on ...

Additionally, 51% of patients achieved complete disappearance of polypoidal lesions—the damage to blood vessels that typifies PCV. Another positive result was that 80% of patients had no fluid ...

Professor Gemmy Cheung, Singapore Eye Research Institute, presented prespecified subgroup analysis of PCV patients enrolled in Opthea’s Phase 2b clinical trial of OPT-302 in combination with ...